

19/529206 #5/A  
528 Rec PCT/PTO 07 APR 2000  
M.C.

PATENT

DOCKET NO. 2026-4269US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Wang, Rong-Fu

U.S. NATIONAL APPLICATION  
OF INTERNATIONAL  
APPLICATION NO. :

PCT/US98/19609

INTERNATIONAL FILING  
DATE :

21 September 1998

PRIORITY DATE :

8 October 1997

FOR :

NOVEL HUMAN CANCER ANTIGEN  
NY-ESO-1/CAG-3 AND GENE ENCODING  
SAME

GROUP ART UNIT :

To be assigned

EXAMINER :

To be assigned

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the U.S. National Application filed under 35 U.S.C.

§371, please enter the Amendment under Article 34 and amend the following claims without  
prejudice:

In the claims:

sub E3  
A1  
cm.t  
P1.12 4/8 (Amended) A cancer peptide, portion or derivative thereof according  
to any one of claims [claim] <sup>1-3</sup> ~~2-4~~ or <sup>4</sup> ~~5~~ wherein the cancer peptide is immunologically  
recognized by HLA restricted cytotoxic T lymphocytes.

534128\_1